Cardiomyopathies and Adrenal Diseases.
Cushing’s syndrome
adrenal disease
cardiomyopathy
endomyocardial biopsy
pheochromocytoma
primary aldosteronism
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
17 Jul 2020
17 Jul 2020
Historique:
received:
29
04
2020
revised:
17
06
2020
accepted:
14
07
2020
entrez:
26
7
2020
pubmed:
28
7
2020
medline:
17
2
2021
Statut:
epublish
Résumé
Cardiomyopathies are myocardial disorders in which heart muscle is structurally and/or functionally abnormal. Previously, structural cardiomyocyte disorders due to adrenal diseases, such as hyperaldosteronism, hypercortisolism, and hypercatecholaminism, were misunderstood, and endomyocardial biopsy (EMB) was not performed because was considered dangerous and too invasive. Recent data confirm that, if performed in experienced centers, EMB is a safe technique and gives precious information about physiopathological processes implied in clinical abnormalities in patients with different systemic disturbances. In this review, we illustrate the most important features in patients affected by primary aldosteronism (PA), Cushing's syndrome (CS), and pheochromocytoma (PHEO). Then, we critically describe microscopic and ultrastructural aspects that have emerged from the newest EMB studies. In PA, the autonomous hypersecretion of aldosterone induces the alteration of ion and water homeostasis, intracellular vacuolization, and swelling; interstitial oedema could be a peculiar feature of myocardial toxicity. In CS, cardiomyocyte hypertrophy and myofibrillolysis could be related to higher expression of atrogin-1. Finally, in PHEO, the hypercontraction of myofilaments with the formation of contraction bands and occasional cellular necrosis has been observed. We expect to clear the role of EMB in patients with cardiomyopathies and adrenal disease, and we believe EMB is a valid tool to implement new management and therapies.
Identifiants
pubmed: 32709015
pii: ijms21145047
doi: 10.3390/ijms21145047
pmc: PMC7404306
pii:
doi:
Substances chimiques
Catecholamines
0
Aldosterone
4964P6T9RB
Hydrocortisone
WI4X0X7BPJ
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
Endocr Rev. 2003 Jun;24(3):278-301
pubmed: 12788800
Kidney Int. 1999 Oct;56(4):1400-12
pubmed: 10504492
Heart Fail Rev. 2014 Nov;19(6):815-24
pubmed: 24398587
N Engl J Med. 2003 Apr 3;348(14):1309-21
pubmed: 12668699
Circulation. 2006 Apr 11;113(14):1807-16
pubmed: 16567565
J Hypertens. 2002 Aug;20(8):1465-8
pubmed: 12172301
J Am Coll Cardiol. 2007 Nov 6;50(19):1914-31
pubmed: 17980265
Circ Cardiovasc Imaging. 2012 Nov;5(6):740-7
pubmed: 23019275
Cell. 2004 Apr 30;117(3):399-412
pubmed: 15109499
Am Heart J. 2001 Jan;141(1):41-6
pubmed: 11136485
Endocrine. 2018 May;60(2):372
pubmed: 28646376
Curr Hypertens Rep. 2000 Jun;2(3):327-34
pubmed: 10981167
J Am Coll Cardiol. 2016 Jan 5;67(1):116-7
pubmed: 26764074
Circulation. 2013 Oct 1;128(14):1531-41
pubmed: 24004501
Medicine (Baltimore). 2018 Dec;97(50):e13369
pubmed: 30557989
J Cell Physiol. 2017 Apr;232(4):806-817
pubmed: 27403897
J Hum Hypertens. 2010 May;24(5):363-6
pubmed: 20130596
N Engl J Med. 1966 May 19;274(20):1102-8
pubmed: 5932021
Medicine (Baltimore). 2015 Dec;94(50):e2198
pubmed: 26683930
J Am Coll Cardiol. 2006 Dec 5;48(11):2293-300
pubmed: 17161262
N Engl J Med. 1999 Sep 2;341(10):709-17
pubmed: 10471456
Hypertension. 1996 May;27(5):1039-45
pubmed: 8621194
J Hypertens. 2014 Oct;32(10):2022-9; discussion 2029
pubmed: 24979305
Biochem Biophys Res Commun. 2001 Feb 9;280(5):1300-6
pubmed: 11162670
Am J Hypertens. 2006 Jan;19(1):13-8
pubmed: 16461184
Int J Cardiol. 2019 Oct 1;292:141-147
pubmed: 31256994
Int Heart J. 2016;57(2):254-7
pubmed: 26973259
J Endocrinol Invest. 2009 Oct;32(9):739-45
pubmed: 19564719
Lancet Diabetes Endocrinol. 2018 Jan;6(1):41-50
pubmed: 29129575
J Clin Endocrinol Metab. 2016 May;101(5):1889-916
pubmed: 26934393
Nat Clin Pract Cardiovasc Med. 2008 Jan;5(1):22-9
pubmed: 18094670
Vasc Health Risk Manag. 2005;1(4):291-9
pubmed: 17315601
Am J Med Sci. 2009 Sep;338(3):252-3
pubmed: 19687733
Eur J Endocrinol. 2010 Feb;162(2):331-40
pubmed: 19933822
Kidney Int. 2004 Jul;66(1):1-9
pubmed: 15200407
Eur Heart J. 2009 Feb;30(4):469-77
pubmed: 19066207
Cardiovasc Drugs Ther. 2010 Aug;24(4):345-50
pubmed: 20676926
Orphanet J Rare Dis. 2006 Dec 08;1:49
pubmed: 17156452
Circulation. 2014 Mar 25;129(12):1348-9
pubmed: 24664219
Circ Cardiovasc Imaging. 2016 Jun;9(6):
pubmed: 27307552
Best Pract Res Clin Endocrinol Metab. 2006 Sep;20(3):467-82
pubmed: 16980206
Circ Cardiovasc Imaging. 2016 Apr;9(4):e004569
pubmed: 26994116
High Blood Press Cardiovasc Prev. 2009 Dec;16(4):183-93
pubmed: 23334910
J Hypertens. 2012 Aug;30(8):1606-13
pubmed: 22688266
J Card Fail. 2004 Dec;10(6):511-8
pubmed: 15599842
Horm Metab Res. 2016 Apr;48(4):238-41
pubmed: 26983926
Clin Endocrinol Metab. 1980 Nov;9(3):543-68
pubmed: 6111405
Can J Physiol Pharmacol. 2009 Jul;87(7):493-514
pubmed: 19767873
J Am Coll Cardiol. 2003 Jun 18;41(12):2275-9
pubmed: 12821259
Int J Cardiol. 2009 May 29;134(3):e138-40
pubmed: 18579235
Int J Cardiol. 2017 Dec 15;249:319-323
pubmed: 29121733
J Clin Endocrinol Metab. 2010 May;95(5):2391-8
pubmed: 20194710
J Clin Endocrinol Metab. 2003 Jun;88(6):2527-33
pubmed: 12788849
Hypertension. 2007 Nov;50(5):911-8
pubmed: 17893375
Hypertens Res. 2005 May;28(5):447-55
pubmed: 16156509
Hypertension. 2001 Nov;38(5):1227-32
pubmed: 11711528